Scribe Therapeutics Plans IPO on Nasdaq
Biotechnology company Scribe Therapeutics has announced plans to pursue an initial public offering (IPO) on the Nasdaq stock exchange under the ticker symbol 'SCTX'. The firm is developing genetic medicines for cardiometabolic disorders, with its lead candidate targeting high cholesterol. It aims to leverage epigenetic silencing technology as a novel approach in gene therapy.
Topics: biotech CRISPR gene_editing IPO